BioPharma Terug naar discussie overzicht

Leuk , kansrijk bedrijfje

1. [verwijderd] 16 januari 2007 15:57

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   eFoodSafety.com, Inc. Completes Successful Double Blind Phase I Clinical Study Meeting FDA Guidelines Demonstrating the Positive Effect of Cinnergen(TM) in the Management of Diabetes
   Tuesday January 16, 9:50 am ET
   Results from 50-Patient Controlled Study Conducted by Bucks County Clinical Research Center Surpass Expectations
   
   SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced that it has completed a Double Blind Phase I Study on Cinnergen(TM), an all natural liquid nutritional supplement designed to regulate blood sugar. The clinical study was conducted by Bucks County Clinical Research Center, which has been doing research for over 20 years for major pharmaceutical companies worldwide. Bucks County Clinical Research Center (www.bccrinc.com) is a fully licensed FDA research center.
   
   ADVERTISEMENT
   The study followed 50 patients with Type I and Type II diabetes over a 90-day period and reported results from a Quality of Life survey completed by each patient. The results from the study showed that 52% of the patients taking 1 ounce of Cinnergen(TM) each day exhibited well controlled blood sugars by using Cinnergen(TM) alone. The remaining 48% of the patients who used 1 ounce of Cinnergen(TM) with their previously prescribed diabetic medications were able to decrease the amount of their medications in order to effectively control their diabetes.
   
   The study also measured the Hemoglobin A1C levels at the beginning and at the conclusion of the study. The diabetic patients on only Cinnergen(TM) had an impressive 70% improvement in this important medical monitoring tool which gives an accurate estimate of long-term blood sugar control.
   
   An impressive 75% of study subjects reported positive changes in their Quality of Life, such as convenience of use, pleasant taste, and increase in energy level, as well as improvement in sleep habits, mental alertness, mood, libido, dietary habits, and an overall feeling of well being. They also reported a marked decrease in illness.
   
   The conclusion by Bucks County Clinical Research Center is that all patients, pre-diabetic or diabetic, would benefit from the use of Cinnergen(TM) on a daily basis.
   
   Patricia Gruden, President and CEO of eFoodSafety.com, Inc., stated, "With these positive, clinically demonstrated results, which exceeded expectations, we will be able to provide major retailers the opportunity to present Cinnergen(TM) to their customers with confidence. We expect Cinnergen(TM) sales to grow significantly as we market our proven claims to our advertisers and retailers, assuring them that they are providing a well studied and quality product that will impact and improve the health and well being of their consumers."
   
   About eFoodSafety.com, Inc.
   
   eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 - that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, which has been clinically proven to facilitate and improve the appearance, redness, and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line. The company is also owner of Cinnergen(TM), a clinically studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com). The company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.
   
   Please visit the Company's website at: www.efoodsafety.com.
   
   Safe Harbor Forward-Looking Statements
   
   Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
2. [verwijderd] 17 januari 2007 10:19

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Even pumpen: gisteren weer +10%.
   Leest allen de bovenstaande berichtensequentie eens door. Credibility wordt sterker, kan een knaller worden.
3. [verwijderd] 17 januari 2007 11:15

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   getipt door yellow, toen voor de gein een aantal gekocht op 31 ct en kort daarna verkocht op 44 ct in de 1e helft van vorig jaar,
   
   bleek achteraf 10% onder de hoogste koers te zijn. staat nu weer op 25 ct na een laag van 16 ct.
   
   wat een rotzooi allemaal.
4. [verwijderd] 18 januari 2007 15:13

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   eFoodSafety.com Announces Cinnergen(TM) Now Distributed Through Cardinal Health
   Thursday January 18, 8:30 am ET
   Company Welcomes Cardinal Health, Rated #19 on Fortune 500 List with Annual Global Sales in Excess of $81 Billion, as Newest Cinnergen Distributor
   
   SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a company dedicated to improving health conditions around the world through innovative products and technologies, today announced that Cardinal Health (NYSE:CAH - News) has commenced purchasing of Cinnergen(TM), an all natural liquid nutritional supplement designed to regulate blood sugar.
   
   Cardinal Health (www.cardinalhealth.com) is one of the largest providers of logistics services to the pharmaceutical industry, distributing products and providing services to thousands of retail, alternate care, mail order and hospital pharmacies. Cardinal Health is also the largest provider of specialized nuclear pharmaceuticals used to diagnose and treat conditions such as cancer and heart disease.
   
   Serving more than 33,000 pharmacy locations, Cardinal Health provides empowering solutions to help Community/Independent/Retail pharmacies better serve their customers. Cardinal Health is dedicated to understanding the unique challenges Community/Independent/Retail pharmacies face and deliver solutions designed to meet their needs.
   
   Patricia Gruden, President and CEO of eFoodSafety.com, Inc., stated, "We are very pleased to add Cardinal Health to our growing list of Cinnergen(TM) distributors. Cardinal Health is a premiere global healthcare company with a commitment to customer service and operational excellence."
   
   About eFoodSafety.com, Inc.
   
   eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1, that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, which has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line. The company is also owner of Cinnergen(TM), a clinically studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com). The company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.
   
   Please visit the company's website at: www.efoodsafety.com.
   
   Safe Harbor Forward-Looking Statements
5. [verwijderd] 18 januari 2007 16:49

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Slowly squeezing...
6. [verwijderd] 19 januari 2007 16:08

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Hij gaat weer op weg...
7. [verwijderd] 19 januari 2007 16:56

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   eFoodSafety.com Announces That Cinnergen(TM) Has Added USA Drug and Dr. Leonard's to Its Growing List of Retail Distributors
   Friday January 19, 9:55 am ET
   Successful Clinical Study Leading to Increasing Retailers' Demand for Distribution
   
   SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced that after a very successful clinical study demonstrating the effectiveness of Cinnergen(TM) on diabetes, many other distributors have been requesting the product for resale. Cinnergen(TM) is an all natural liquid nutritional supplement designed to regulate blood sugar.
   
   USA Drug (www.usadrug.com), a family-owned and operated company, provides a down-home friendly, atmosphere, while designed to handle a large number of retail customers. USA Drug strives to maintain a continuously evolving retail format to better provide its customers the best products and services at the lowest competitive prices.
   
   Dr. Leonard's Healthcare (www.drleonards.com) is a leading catalog healthcare provider offering a large selection of healthcare products encouraging people to keep fit and strong. From providing pills and supplements to improve one's overall health, Dr. Leonard's is there for its customers, ensuring that consumers have available all of their necessary vitamins, nutrients and supplements.
   
   Patricia Gruden, President and CEO of eFoodSafety.com, Inc., stated, "We are continuing to aggressively build our Cinnergen(TM) retail distribution network. As part of this initiative, we are pleased to add USA Drug and Dr. Leonard's to our growing list of premier vendors. We believe these combined with the recent additions of Kroger's, Kerr Drugs and Cardinal Health all bode very well for increasing Cinnergen(TM) sales volumes as well as presenting an established distribution network with potential future cross-selling opportunities."
   
   Mrs. Gruden further commented, "We anticipate that with the clinical study now successfully completed, with the results demonstrating Cinnergen's effectiveness on all types of diabetes, that our goal of having this product in over 20,000 retail locations by the end of 2007 is attainable"
   
   About eFoodSafety.com, Inc.
   
   eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) -- EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line. The company is also owner of Cinnergen(TM), a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com). The company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.
   
   Please visit the Company's website at: www.efoodsafety.com.
   
   Safe Harbor Forward-Looking Statements
8. [verwijderd] 24 januari 2007 13:35

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   eFoodSafety.com, Inc. Prepares for National Launch of New Cholesterol Product into This Multi-Billion Dollar Market
   
   Tuesday January 23, 8:30 am ET
   Multi-faceted Nutritional Supplement Cinnechol(TM) Designed to Naturally Reduce Total Cholesterol Levels without Side Effects now Formulated and Ready for Launch
   
   SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced that its cholesterol product, Cinnechol(TM), is ready for national retail distribution through the Company's current and growing distribution channels.
   
   The formulation and packaging of Cinnechol(TM) is complete and the Company is planning a national advertising campaign to introduce the product to the general public within the next 60 days.
   
   Cinnechol(TM) is a new multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects while helping to decrease LDL (bad) cholesterol, lower triglycerides, and lower the LDL to HDL (good) cholesterol ratio.
   
   Cinnechol(TM)'s all natural ingredients work synergistically to decrease the viscosity, or thickness of the blood, which allows for better circulation. Additionally, the blend of nutrients in Cinnechol(TM) can assist in fighting inflammation, vital to the health of the heart and blood vessels. The ingredients in Cinnechol(TM) also can help increase levels of CoQ10, an essential enzyme needed for healthy heart muscle function.
   
   Naturally treating cardiovascular disease (CVD) is essential as 1 in 5 Americans over the age of 20 have high cholesterol, a major factor contributing to CVD. Approximately 1.4 million people die annually in the US due to heart disease, the leading cause of death in this country since 1900. The annual national cost of all treatments for cardiovascular disease is close to $400 billion.
   
   Patricia Gruden, President and CEO of eFoodSafety.com, Inc., stated, "We are excited to bring to market a treatment working to help control cholesterol, a major health risk in this country. We believe the important difference between Cinnechol(TM) and the products of major pharmaceutical companies is its effectiveness without any associated side effects."
   
   About eFoodSafety.com, Inc.
   
   eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line. The company is also owner of Cinnergen(TM), a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com). The company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.
   
   Please visit the Company's website at: www.efoodsafety.com.
   
   Safe Harbor Forward-Looking Statements
9. Nel 24 januari 2007 13:42

   auteur info

   • Nel

     Lid sinds: 04 apr 2004

     Laatste bezoek: 04 feb 2025

   • Aanbevelingen

     Ontvangen: 1416

     Gegeven: 219

   •    Aantal posts: 27.770

   finance.yahoo.com/q?s=EFSF.OB
10. [verwijderd] 24 januari 2007 14:37

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    EfoodSafety is dit jaar op een aantal positieve persberichten gestegen van ongeveer 0,18 naar 0,34. De trigger voor de stijging was een aantal goede berichten, m.n. het feit dat hun huidige lead product Cinnergen - voor diabetis/regulering bloedsuikerspiegel - positief uit klinische testen komt, en door een aantal relevante ketens in het assortiment is opgenomen. De positieve testresultaten leiden op dit moment tot sterke belangstelling.
    
    Daarnaast is een gewasbeschermingsmiddel positief getest door het USDepartment of Agriculture. Het middel werd getest vanaf juni 2005. De testen leiden waarschijnlijk tot een joint-licensing agreement tussen beide partijen. Dit geeft het produkt een sterke vertrouwensbasis; gevoegd bij het feit dat het momenteel meest gebruikte produkt wegens schadelijkheid voor het milieu in veel landen in de ban is/wordt gedaan.
    
    Deze produkten, samen met het scala aan produkten hieronder, kunnen de omzet van efsf een enorme impuls geven. Al wordt maar 10% van de verwachtingen bewaarheid, dan hebben we het nog over een potentieel dat ruim boven de 1 dollar ligt.
    
    Enige tijd geleden rapporteerde efsf een (naked) shortpositie van zo'n 17 miljoen stuks. De squeezeprijs zou liggen bij ongeveer 32,5 cent.
    
    De laatste week zijn de omzetten zeer fors, gevoed door een aardig setje persberichten op rij. Waarschijnlijk veel instappers, i.c.m. short covering.
    Meer goed nieuws valt te verwachten. (Echt) positief vogelgriepnieuws kan tot een explosie leiden, of bijv. een trading-update m.b.t. de omzet van Cinnergen of Talsyn.
    
    De koers is beland bij de weerstand die ligt bij de zone 0,34-0,35. Die weerstand is behoorlijk, maar er wordt al flink kopjes gegeven. Daarboven ligt voor zover ik dat kan bezien nog wat weerstand bij 0,37 en 0,4 en dan een tijd lang niks.
    
    Enig slordig rekenwerk m.b.t. koerspotentieel:
    Cinnergen/diabetis:
    Van cinnergen wordt ongeveer 1 ounce per dag gebruikt. 32 ounce kost zo'n 30 dollar, oftewel 640 dollar per jaar.
    De VS kent zo'n 15 miljoen geregistreerde diabetici, in werkelijkheid zijn het er meer. Daarbij is er sprake van toenemend bewustzijn v.w.b. het gebruik en de gevolgen van suiker.
    
    Als 1 procent van de diabetici Cinnergen zou gebruiken, is dat een bruto-omzet van 96 miljoen dollar. Als efsf daarvan 40% zou binnenharken hebben we het over 38,4 miljoen.
    Op de 150 mln uitstaande aandelen is dat ,255 cent per aandeel.
    Stel dat ze 5 cent per aandeel netto verdienen, dan is met een koers/winstje van 10 een koers van 50 cent gerechtvaardigd.
    Als die percentages wat hoger uitvallen, of een van de andere produkten slaat goed aan: do the math.
    
    Er was voldoende geld in kas om het uit te zitten tot het einde van het gebroken boekjaar 2006/2007.
    
    Zie hieronder, en de rest van deze draad voor hun andere produkten. Veel markten met een totale omvang van honderden miljoenen/miljarden.
    
    Dit speculatieve (!?) aandeel is toch te leuk om waar te zijn?
    
    Kom op connect, verpats wat Covad en spring er weer eens in...
    Er zitten nog heel veel shorts op hele hete kolen.
    
    Even op een rijtje:
    
    - middel voor diabetici, ter regulering bloedsuikerspiegel (Cinnergen) positief uit klinische testen. Cinnergen is nu op zo'n 25.000 plaatsen in de VS verkrijgbaar. Het aantal afnemers/suppliers groeit, zeker na de officiële testresultaten.
    www.cinnergen.com/
    
    - pureffect, een middel tegen acné zal in kw I 2007 worden gelanceerd. De marketing wordt verzorgd door ck41, met een geprognostiseerde bruto-opbrengst van 100 miljoen dollar. CK41 verzorgt 'quality direct response infomercial campaigns' a la de abdominizer. Lullige commercials, maar wel goed voor een paar honderd miljoen in verkopen. Kosten voor produktie, distributie en marketing zijn voor CK41. (omzet van de grootste concurrent afgelopen jaar > 300 miljoen)
    
    Percentage omzet/winst dat efsf toevalt bij mij niet bekend.
    www.ck41.com/press/acne.htm
    
    - parallel aan pureffect is er Talsyn, een anti-litteken creme, die wordt gedistribueerd via MedElite, dat direct aan doktoren en klinieken levert. Ook Talsyn is recent op de markt gekomen, en zal naar verwachting in 2007 relevant bijdragen aan de omzet.
    De verhalen over Talsyn zijn enthousiast te noemen.
    
    www.medeliteinc.com/
    www.talsyn.com
    Enig klinisch onderzoek
    www.talsyn.com/pages.asp?pageid=21665
    tinyurl.com/33j2vm
    
    - Cinnechol: cholestorol, eveneens op natuurlijke basis. Cinnechol kan worden verkocht via dezelfde, reeds bestaande en groeiende kanalen als voor Cinnergen.
    
    - nematoden/gewasbescherming: oraphyte. Voor oraphyte wordt hoogstwaarschijnlijk tussen 60-120 dagen een joint-licensing agreement met het USDepartment of Agriculture gesloten, wat het produkt een flinke boost kan geven. Op dit moment wordt vooral methyl-bromide gebruikt, maar wegens de schadelijke gevolgen voor de ozonlaag wordt dit al op veel plaatsen verboden. De US worden verwacht/gehoopt te volgen.
    
    Dan hebben we nog:
    - Een middel tegen Anthrax, Clostridium Sporogenes and Bacillus Subtilis
    - Tubercolose: trymicin
    - Malaria: auromoxin
    - vogelgriep/influenza A: citroxin (al goedgekeurd door het EPA - environmental protection agency.)
    citroxin wordt getest in Thailand, en de persberichten zijn louter positief.(...) Maar al zouden ze het alleen in Thailand maar gebruiken om kippenhokken mee te besproeien, dan is het nog een winner.
    Het Thaise biotechbedrijf dat het citroxin test (op vogelgriep en influenza A):
    www.innovabiotechnology.com/contact.html
    

    Bijlage:
11. [verwijderd] 24 januari 2007 14:50

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    www.otcjournal.com/profile.php?compan...
    
    (Ter aanvulling vorige post: cardinal health als distributeur alleen heeft 33.000 verkooppunten. Als elk daarvan aan 4 mensen cinnergen verkopen, hebben we het, o.b.v. dagelijks gebruik, over 84,5 miljoen omzet.)
12. [verwijderd] 25 januari 2007 13:30

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Kees33 schreef:

    Dan hebben we nog:
    - Een middel tegen Anthrax, Clostridium Sporogenes and Bacillus Subtilis
    - Tubercolose: trymicin
    - Malaria: auromoxin
    - vogelgriep/influenza A: citroxin (al goedgekeurd door het EPA - environmental protection agency.)
    citroxin wordt getest in Thailand, en de persberichten zijn louter positief.(...) Maar al zouden ze het alleen in Thailand maar gebruiken om kippenhokken mee te besproeien, dan is het nog een winner.
    Het Thaise biotechbedrijf dat het citroxin test (op vogelgriep en influenza A):
    www.innovabiotechnology.com/contact.html
    

    Ziekte van Lhyme nog vergeten te noemen. Daarmee zijn testen begonnen in maart 2006, en op de webcast van oktober 2006 werden in the very near future resultaten beloofd. ('amazing results')
    
    Om met Joy Division te spreken:
    Where will it end?
    Where will it end?
13. [verwijderd] 25 januari 2007 16:14

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Alweer een persbericht. Nu die 0,35 nog flink pakken.
    
    eFoodSafety.com, Inc.'s Subsidiary Knock-Out Technologies, Ltd. Reports that the United States Department of Agriculture Has Filed a New and Novel Use Patent for OraPhyte(TM)
    Thursday January 25, 10:05 am ET
    USDA Results to Confirm and Support Effectiveness of OraPhyte(TM) in Combating Plant-Parasitic Nematodes that Cause an Estimated Annual Crop Loss of $100 Billion Globally
    
    SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced through its wholly-owned subsidiary, Knock-Out Technologies, Ltd. that the United States Department of Agriculture (USDA) has filed a new and novel use patent for Knock-Out Technologies' OraPhyte(TM), a product derived from the Company's patent pending Citroxin product that kills and controls plant-parasitic Nematodes.
    
    Plant-parasitic Nematodes are microscopic worms that cause an estimated annual crop loss of $100 billion globally. In the U.S., farmers face over $10 billion in annual losses due to Nematodes. OraPhyte(TM) has been designed to combat this costly issue.
    
    The product was formulated and developed by Knock-Out Technologies, but the extensive testing on plant-parasitic nematodes was conducted by the USDA. It will be the USDA's results that are used to confirm and support the effectiveness of OraPhyte(TM) while marketing the product.
    
    Robert Bowker, President of Knock-Out Technologies, stated, "This is another major step in bringing this product to market. We believe we have an environmentally-safe and highly effective product that can be the replacement for environmentally-hazardous methyl bromide, the most widely used product currently controlling this $100 billion problem."
    
    Mr. Bowker added, "We anticipate the introduction of OraPhyte(TM) to be warmly received within its market, especially with USDA data to reinforce its effectiveness."
    
    About eFoodSafety.com, Inc.
    
    eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line. The company is also owner of Cinnergen(TM), a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com) and Cinnechol(TM), a new multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects. The company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.
    
    Please visit the Company's website at: www.efoodsafety.com.
    
    Safe Harbor Forward-Looking Statements
14. [verwijderd] 25 januari 2007 17:23

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    In het kader van enige dd, heb ik wat emails gestuurd aan betrokken bedrijven, die de marketing van efsf produkten verzorgen.
    
    Dit was de reactie van de ceo van MedX, die de professionele scar cream gaan verzorgen. Dit produkt wordt met verkocht aan doktoren en klinieken. Geen retail dus.
    
    Dit was zijn reactie:
    Sir,
    
    The acceptance of our customers has been overwhelmingly positive;that
    is, once they give it a try. The scar market is huge. However, most/if
    not all of the scar creams currently on the market don't do a whole lot.
    This has brought about a strong feeling of skepticism among the
    physician community which we need to overcome. On a positive note,
    results from Talsyn definetely exceed what our competitors currently
    offer.
    
    Our sales of new accounts have been slower then I originally estimated.
    My estimation was formulated purely on conjecture though. I have a lot
    of experience rolling out new products to the aesthetic market.
    However, every product is unique and has a differnet set of challenges.
    
    To answer your question reagrding sales, I would say we are not in line
    with my original estimates for new accounts. However, we are exceeding
    my estimates on reorders from existing accounts. I think this is one of
    these things where it is going to take time to get the word out and gain
    credibility. Once we establish a critical mass, sales should increase
    exponentially.
    
    Hopefully, I answered your questions to your satisfaction.
    
    Respectfully,
    
    Mark
    
    Mark A. Rubino
    Chief Executive Officer
    MedX, Inc.
    279 Great Valley Parkway
    Malvern, PA 19355
    Phone: 610.971.**** (weggehaald door mij)
    Fax: 610.971.2200
15. [verwijderd] 29 januari 2007 16:01

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    eFoodSafety.com, Inc. Announces Addition of Internet Retailers CVS.com, Amazon.com and drugstore.com to Expanding List of Cinnergen(TM) Retail Distributors
    Monday January 29, 9:40 am ET
    E-Commerce Initiative to Bolster Brand Building and Complement Traditional Sales Efforts
    
    SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced that CVS.com, Amazon.com, and drugstore.com are now carrying Cinnergen(TM), the Company's all natural, liquid nutritional supplement designed to regulate blood sugar.
    
    ADVERTISEMENT
    CVS.com (www.cvs.com) offers prescription and non-prescription drugs for in-store pickup or home delivery, home medical supplies, CVS store items and online exclusives. CVS.com is the official website for CVS/pharmacy, America's largest retail pharmacy, operating more than 6,200 retail and specialty pharmacy stores in 43 states and the District of Columbia.
    
    Amazon.com (NASDAQ:AMZN - News), www.amazon.com, a Fortune 500 company based in Seattle, opened its virtual doors on the World Wide Web in July 1995 and today offers Earth's biggest selection. Amazon.com seeks to be Earth's most customer-centric company, where customers can find and discover anything they might want to buy online, and endeavors to offer customers the lowest possible prices. Amazon.com and third-party sellers offer millions of unique new, refurbished, and used items in categories such as health and personal care, jewelry and watches, gourmet food, sports and outdoors, apparel and accessories, books, music, DVDs, electronics and office, toys and baby, and home and garden.
    
    drugstore.com (www.drugstore.com) is a leading online drugstore and information site for health, beauty, wellness, personal care, and pharmacy products. The drugstore.com online store provides a convenient, private, and informative shopping experience that encourages consumers to buy products essential to healthy everyday living.
    
    Patricia Gruden, President and CEO of eFoodSafety.com, Inc., stated, "We are pleased to announce that our internet presence is growing through the addition of these three prominent and respected internet retailers. We are confident this initiative will lead to increased sales of the product in coming months. We again remain firmly committed to our goal of having this clinically-proven and effective product in over 20,000 retail locations by year's end."
    
    About eFoodSafety.com, Inc.
16. miekemuis 8 februari 2007 23:01

    auteur info

    • miekemuis

      Lid sinds: 18 mrt 2004

      Laatste bezoek: 12 nov 2024

    • Aanbevelingen

      Ontvangen: 82

      Gegeven: 1002

    •    Aantal posts: 315

    eFoodSafety.com Announces That The KonLin Letter Has Issued a Featured Stock Follow-up Report on EFoodSafety.com, Inc. in Its February 2007 Issue
    Thursday February 8, 10:50 am ET
    25 Year Old Top Performing Independent Market Letter Calls Company a Ground Floor Opportunity with Explosive Growth Potential and Forecasts a Short-Term Target Stock Price of $2.00
    
    SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced that The KonLin Letter issued a Featured Stock Follow-Up Report on eFoodSafety.com, Inc. in its February 2007 issue. The KonLin Letter reiterates its "Strong Buy" recommendation of EFSF stock.
    Konrad Kuhn, editor of The KonLin Letter, said that "the bulls smell blood, since according to Buyins.net (www.buyins.net), a short squeeze could take place and a buying panic could occur if the stock closes above $0.3620."
    
    Mr. Kuhn further commented in another section of the report, "Big Pharma buys out two kinds of companies, those that give it a huge competitive advantage and those that can take its edge away."
    
    The KonLin Letter states that EFSF is a ground floor opportunity with explosive growth potential and has already established positive fundamentals.
    
    The KonLin Letter, a 25-year-old investment advisory newsletter noted for its fundamental and technical analysis of individual stocks and market movements, does not accept compensation for its analyses of selected companies. The report includes a review of the latest developments of the Company, the Company's market position and potential advantages, along with fundamentals and statistics.
    
    Mr. Kuhn cited the following reasons for his February 2007 follow-up recommendation:
    
    Highlighted OraPhyte(TM), a $100 billion solution to plant-parasitic nematodes. Company and USDA had jointly filed a patent application and are currently working together on finalizing a Licensing Agreement between the parties - multi-billion dollar market size.
    Clinical study on Cinnergen(TM) diabetes product, which was a Double Blind Phase I study that met FDA guidelines and surpassed expectations. Major retailers are anticipated to begin distributing the product shortly.
    Company reduced its issued and outstanding shares by 20% and has taken 30 million shares out of the float.
    Knock-Out Technologies completed and tested Trimyacin(TM), a Tuberculosis product, Auromoxin(TM), a Malaria product, and Occusyn(TM), a Lyme Disease product - all with favorable results. Further necessary testing is planned.
    Company announced name PurEffect(TM) and secured trademark of anti-acne product and will be announcing celebrity spokesperson(s) shortly.
    Mr. Kuhn commented, "Patricia Gruden continues to do an excellent job at the helm of eFoodSafety, and in my opinion, she's not done yet. I believe the Cinnergen(TM) success will be followed by many other products. The recent announcement of its cholesterol product, Cinnechol(TM), to be distributed through the Company's already existing and growing distribution channels was an excellent strategic move. I expect the Knock-Out division, which I have always classified as the 'crown jewel' of the eFoodSafety, will have a few more pleasant surprises in store for investors shortly."
    
    "I've said it many times before and I'll continue to say it, never in my 25-year history as a newsletter writer and analyst, have I seen a Company with such dramatic upside potential in so many different multi-billion dollar markets," further added Mr. Kuhn.
    
    Patricia Gruden, President and CEO of eFoodSafety.com, Inc., stated, "The Company is pleased that The KonLin Letter has elected to continue following eFoodSafety's progress this year. The KonLin Letter is a highly-respected, long-established, Small-Cap newsletter which receives no compensation from the companies reviewed whose forecasts, commentary, and opinions are arrived at based solely on its own analysis."
    
    About KonLin Research & Analysis Corp.
    
    The KonLin Letter, www.KonLin.com, chooses low-priced stocks to analyze, with an emphasis on emerging growth and special situations poised for explosive price appreciation. The KonLin Letter has constantly been one of the leading publications on Wall Street. It has been rated one of the best performing market letters in the nation, offering a unique service that each month recommends five low-priced selections, including a featured stock of the month. EFSF was the featured stock in the month of September 2005.
    
    About eFoodSafety.com, Inc.
    
    eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line. The Company is also owner of Cinnergen(TM), a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com) and Cinnechol(TM), a new multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects. The Company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.
    
    Please visit the Company's website at: www.efoodsafety.com.
    
    Safe Harbor Forward-Looking Statements
    
    Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
    
    Contact:
    Redwood Consultants, LLC
    Jens Dalsgaard, 415-884-0348
    
    ---------------------
17. [verwijderd] 15 februari 2007 19:33

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    eFoodSafety.com, Inc. Announces Wall Street Resources, Inc. Releases an Analytical Profile on eFoodSafety.com, Inc. with 12-Month Target Value of $2.11
    Thursday February 15, 8:30 am ET
    
    SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced the release of an analytical profile on the Company by respected micro-cap analyst Paul Silver, Director of Research for Wall Street Resources, Inc., which contains a 12-month target value for EFSF of $2.11 per share.
    ADVERTISEMENT
    
    
    The free report is available at: www.wallstreetresources.net/EFSFPP.asp. The 41-page report includes detailed information on the Company's business model, products, industry, valuation, management and risks. Wall Street Resources, Inc. is a professional research and consulting firm whose principals have over 15 years of experience providing analysis for emerging growth companies and information to the investment community.
    
    Patricia Gruden, President and CEO of eFoodSafety.com, Inc. stated, "Our collaboration with Wall Street Resources in an effort to create an organized presentation showcasing our current products, technologies, and works in progress, resulted in a high-quality, in-depth analytical report on eFoodSafety and its subsidiaries. We remain dedicated to our shareholders for their ongoing support and are eager to provide the investment community with this useful research tool."
    
    Mr. Silver stated, "eFoodSafety offers investors an opportunity to potentially capitalize on treatments for some of the world's most costly infectious diseases and conditions. Leveraging its innovative patent-pending technologies, eFoodSafety expects to bring to market treatments for multi-billion dollar conditions such as diabetes and high cholesterol, in addition to treatments for such infectious diseases as malaria and tuberculosis, which combined cost the world almost $200 billion annually."
    
    About eFoodSafety.com, Inc.
    
    eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line. The Company is also owner of Cinnergen(TM), a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com) and Cinnechol(TM), a new multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects. The Company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.
    
    Please visit the Company's website at: www.efoodsafety.com.
    
    Safe Harbor Forward-Looking Statements
    
    Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
    
    About Wall Street Resources, Inc.:
    
    Wall Street Resources, Inc. and its affiliated site www.wallstreetresources.net is a leading source for information on publicly traded micro-to-small capital companies. Wall Street Resources (WSR) acts as a conduit between micro-to-small capital company investors and emerging growth companies through its proprietary financial publications, including daily and monthly newsletters as well as comprehensive 20-50 page featured company reports. To sign up to receive WSR's financial publications go to: www.wallstreetresources.net/signup_ba... WSR also provides business consulting services to help corporate executives by writing analytical reports, building financial models, and developing business plans.
    
    Disclaimer -- We, our affiliates, and any officer, director or stockholder or any member of their families may have a position in and may from time to time purchase or sell any securities discussed in our financial publications. There may be instances when fundamental, technical, and quantitative opinions may not be in concert. Our associates may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in our reports. WSR is a consultant to the Company and has received $10,000 in cash and 225,000 shares of 144 restricted stock for due diligence fees and consulting services from January of 2007 through July of 2007.
    
    
18. miekemuis 7 maart 2007 16:01

    auteur info

    • miekemuis

      Lid sinds: 18 mrt 2004

      Laatste bezoek: 12 nov 2024

    • Aanbevelingen

      Ontvangen: 82

      Gegeven: 1002

    •    Aantal posts: 315

    Release Source: eFoodSafety.com, Inc.
    
    eFoodSafety.com, Inc. Receives Initial Purchase Order for Cinnergen(TM) from Wal-Mart
    Wednesday March 7, 9:30 am ET
    Cinnergen(TM) Diabetes Product to be Featured in World's Largest Retailer
    
    SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced that Wal-Mart will soon carry Cinnergen(TM), the Company's clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism.
    ADVERTISEMENT
    
    
    The initial purchase order for the first 500 stores has been received. The Company anticipates Cinnergen(TM) to be carried nationally throughout the entire Wal-Mart chain by mid-June 2007. Wal-Mart operates more than 3,800 facilities in the United States and more than 2,600 more in Argentina, Brazil, Canada, China, Costa Rica, El Salvador, Germany, Guatemala, Honduras, Japan, Mexico, Nicaragua, Puerto Rico and the United Kingdom.
    
    In addition to Wal-Mart, the Company recently announced that both Kroger Supermarkets and Kerr Drug are also now a part of Cinnergen(TM)'s expanding retail distribution network. The Company is continuing its national advertising campaign with CNN and other local television stations to further solidify the Cinnergen(TM) brand.
    
    Patricia Gruden, President and CEO of eFoodSafety.com, Inc. stated, "This is another significant step towards solidifying and growing the Cinnergen(TM) brand. With the recent additions of both Wal-Mart and Kroger's, the world's largest retailer and one of the nation's largest grocery retailers, our retail distribution network has seen a great expansion in recent months. These new sales channels have the potential to result in a very material impact on sales as well as further establishing and enhancing our products retail distribution and presence. We anticipate future shipments to other large and recognizable retailers in the coming months as we move toward our goal of having Cinnergen(TM) marketed in over 20,000 retail locations before the end of 2007."
    
    About Wal-Mart
    
    Wal-Mart Stores, Inc. operates Wal-Mart discount stores, Supercenters, Neighborhood Markets and Sam's Club locations in the United States. The Company operates in Argentina, Brazil, Canada, China, Costa Rica, El Salvador, Guatemala, Honduras, Japan, Mexico, Nicaragua, Puerto Rico and the United Kingdom. The Company's securities are listed on the New York Stock Exchange under the symbol WMT. More information about Wal-Mart can be found by visiting www.walmartfacts.com. Online merchandise sales are available at www.walmart.com.
    
    About eFoodSafety.com, Inc.
    
    eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line. The Company is also owner of Cinnergen(TM), a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com) and Cinnechol(TM), a new multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects. The Company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.
    
    Please visit the Company's website at: www.efoodsafety.com.
    
    Safe Harbor Forward-Looking Statements
    
    Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
    
    Contact:
    Redwood Consultants, LLC
    Jens Dalsgaard, 415-884-0348
    
    --------------------------------------------------------------------------------
    Source: eFoodSafety.com, Inc.
    
    
19. miekemuis 7 maart 2007 16:22

    auteur info

    • miekemuis

      Lid sinds: 18 mrt 2004

      Laatste bezoek: 12 nov 2024

    • Aanbevelingen

      Ontvangen: 82

      Gegeven: 1002

    •    Aantal posts: 315

    koers nu 0.4699 $ (+ 13.23 %), high 0.48 $
    
    Géén interesse, ok dan..
20. miekemuis 7 maart 2007 22:22

    auteur info

    • miekemuis

      Lid sinds: 18 mrt 2004

      Laatste bezoek: 12 nov 2024

    • Aanbevelingen

      Ontvangen: 82

      Gegeven: 1002

    •    Aantal posts: 315

    Slot 0.49 $ (+ 18.07%), niet slecht morgen méér ?